DK1913130T3 - Cellemarkør/ligand-system, hvor markøren er af eph-typen, cellemateriale, som omfatter systemet, fremgangsmåde til fremstilling deraf og proangiogen anvendelse - Google Patents
Cellemarkør/ligand-system, hvor markøren er af eph-typen, cellemateriale, som omfatter systemet, fremgangsmåde til fremstilling deraf og proangiogen anvendelse Download PDFInfo
- Publication number
- DK1913130T3 DK1913130T3 DK06794234.2T DK06794234T DK1913130T3 DK 1913130 T3 DK1913130 T3 DK 1913130T3 DK 06794234 T DK06794234 T DK 06794234T DK 1913130 T3 DK1913130 T3 DK 1913130T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- ephrin
- marker
- ligand
- ephb4
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims description 112
- 239000000463 material Substances 0.000 claims description 66
- 239000003446 ligand Substances 0.000 claims description 54
- 239000003550 marker Substances 0.000 claims description 52
- 102100023721 Ephrin-B2 Human genes 0.000 claims description 37
- 108010044090 Ephrin-B2 Proteins 0.000 claims description 37
- 210000001956 EPC Anatomy 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 210000005087 mononuclear cell Anatomy 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 claims description 17
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 claims description 17
- 239000002243 precursor Substances 0.000 claims description 14
- 102000023732 binding proteins Human genes 0.000 claims description 13
- 108091008324 binding proteins Proteins 0.000 claims description 13
- 239000002771 cell marker Substances 0.000 claims description 13
- 230000001023 pro-angiogenic effect Effects 0.000 claims description 13
- 230000033115 angiogenesis Effects 0.000 claims description 12
- 210000002889 endothelial cell Anatomy 0.000 claims description 12
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 11
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 11
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 11
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 11
- 230000000302 ischemic effect Effects 0.000 claims description 11
- 108010033276 Peptide Fragments Proteins 0.000 claims description 10
- 102000007079 Peptide Fragments Human genes 0.000 claims description 10
- 230000004071 biological effect Effects 0.000 claims description 10
- 210000004700 fetal blood Anatomy 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 210000005259 peripheral blood Anatomy 0.000 claims description 8
- 239000011886 peripheral blood Substances 0.000 claims description 8
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims description 7
- 102100033946 Ephrin-B1 Human genes 0.000 claims description 6
- 108010044099 Ephrin-B1 Proteins 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 206010054880 Vascular insufficiency Diseases 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 230000000250 revascularization Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 208000023577 vascular insufficiency disease Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 206010003230 arteritis Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims 7
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical class 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 102000012803 ephrin Human genes 0.000 description 20
- 108060002566 ephrin Proteins 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102000050554 Eph Family Receptors Human genes 0.000 description 16
- 108091008815 Eph receptors Proteins 0.000 description 16
- 210000003414 extremity Anatomy 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 11
- 230000003511 endothelial effect Effects 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 2
- 108010074415 Angiogenic Proteins Proteins 0.000 description 2
- 102000008076 Angiogenic Proteins Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 108010035597 sphingosine kinase Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 1
- 102100031984 Ephrin type-B receptor 6 Human genes 0.000 description 1
- 102000020086 Ephrin-A1 Human genes 0.000 description 1
- 108010043945 Ephrin-A1 Proteins 0.000 description 1
- 102100023733 Ephrin-B3 Human genes 0.000 description 1
- 108010044085 Ephrin-B3 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 101000938354 Homo sapiens Ephrin type-A receptor 1 Proteins 0.000 description 1
- 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 108010000494 ephrin-A6 Proteins 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000003566 hemangioblast Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508029A FR2889200B1 (fr) | 2005-07-27 | 2005-07-27 | Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique |
| PCT/FR2006/001837 WO2007012764A2 (fr) | 2005-07-27 | 2006-07-27 | Système marqueur cellulaire/ligand, où le marqueur est du type eph, matériau cellulaire comprenant ce système, procédé de préparation et utilisation proangiogénique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1913130T3 true DK1913130T3 (en) | 2016-03-29 |
Family
ID=36353668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06794234.2T DK1913130T3 (en) | 2005-07-27 | 2006-07-27 | Cellemarkør/ligand-system, hvor markøren er af eph-typen, cellemateriale, som omfatter systemet, fremgangsmåde til fremstilling deraf og proangiogen anvendelse |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8338169B2 (enExample) |
| EP (1) | EP1913130B1 (enExample) |
| JP (4) | JP5755829B2 (enExample) |
| CN (1) | CN101273123B (enExample) |
| AU (1) | AU2006273928B2 (enExample) |
| CA (1) | CA2616712C (enExample) |
| DK (1) | DK1913130T3 (enExample) |
| ES (1) | ES2565675T3 (enExample) |
| FR (1) | FR2889200B1 (enExample) |
| IL (1) | IL188938A (enExample) |
| WO (1) | WO2007012764A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2909559B1 (fr) * | 2006-12-06 | 2012-09-07 | Inst Vaisseaux Et Du Sang | Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation |
| AU2008223817A1 (en) | 2007-03-02 | 2008-09-12 | National University Of Ireland, Galway | Osteopontin for the prediction and treatment of cardiovascular diseases |
| FR2957799B1 (fr) * | 2010-03-26 | 2012-08-17 | Inst Des Vaisseaux Et Du Sang | Compositions proangiogeniques, leur procede de preparation et leurs utilisations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4240635C2 (de) * | 1992-12-03 | 1997-07-10 | Lothar Prof Dr Kanz | Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| WO2000031124A2 (en) | 1998-11-20 | 2000-06-02 | Mount Sinai Hospital | Peptides that modulate the interaction of b class ephrins and pdz domains |
| US6610534B2 (en) | 2000-10-05 | 2003-08-26 | Novartis Ag | Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases |
| AU2002243623A1 (en) | 2001-01-26 | 2002-08-06 | Regeneron Pharmaceuticals, Inc. | Methods of imaging and targeting vasculature |
| AU2002311792A1 (en) | 2001-03-30 | 2002-10-15 | President And Fellows Of Harvard College | B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use |
| US20050049194A1 (en) | 2001-11-09 | 2005-03-03 | Jonas Frisen | Use of ephrins and related molecules to regulate cellular proliferation |
| AU2003232457A1 (en) | 2002-05-29 | 2003-12-19 | Curagen Corporation | Compositions and methods of use for an ephrin rreceptor |
| US20040110150A1 (en) | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of Ephrin-B2 expression |
| US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| AU2003900541A0 (en) | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
| AU2004220459B2 (en) | 2003-03-12 | 2010-08-05 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
-
2005
- 2005-07-27 FR FR0508029A patent/FR2889200B1/fr not_active Expired - Lifetime
-
2006
- 2006-07-27 US US11/996,862 patent/US8338169B2/en not_active Expired - Fee Related
- 2006-07-27 EP EP06794234.2A patent/EP1913130B1/fr active Active
- 2006-07-27 CA CA2616712A patent/CA2616712C/fr not_active Expired - Fee Related
- 2006-07-27 AU AU2006273928A patent/AU2006273928B2/en not_active Ceased
- 2006-07-27 CN CN2006800358867A patent/CN101273123B/zh not_active Expired - Fee Related
- 2006-07-27 JP JP2008523415A patent/JP5755829B2/ja not_active Expired - Fee Related
- 2006-07-27 DK DK06794234.2T patent/DK1913130T3/en active
- 2006-07-27 ES ES06794234.2T patent/ES2565675T3/es active Active
- 2006-07-27 WO PCT/FR2006/001837 patent/WO2007012764A2/fr not_active Ceased
-
2008
- 2008-01-22 IL IL188938A patent/IL188938A/en active IP Right Grant
-
2014
- 2014-12-17 JP JP2014255610A patent/JP5981525B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-15 JP JP2016050940A patent/JP6235639B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-21 JP JP2017121385A patent/JP2017169590A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007012764A2 (fr) | 2007-02-01 |
| JP6235639B2 (ja) | 2017-11-22 |
| ES2565675T3 (es) | 2016-04-06 |
| CN101273123B (zh) | 2013-06-26 |
| CN101273123A (zh) | 2008-09-24 |
| IL188938A0 (en) | 2008-04-13 |
| EP1913130B1 (fr) | 2015-12-23 |
| JP2017169590A (ja) | 2017-09-28 |
| JP5755829B2 (ja) | 2015-07-29 |
| AU2006273928B2 (en) | 2012-02-16 |
| IL188938A (en) | 2014-09-30 |
| AU2006273928A1 (en) | 2007-02-01 |
| JP2009505638A (ja) | 2009-02-12 |
| US8338169B2 (en) | 2012-12-25 |
| FR2889200B1 (fr) | 2008-01-04 |
| JP5981525B2 (ja) | 2016-08-31 |
| FR2889200A1 (fr) | 2007-02-02 |
| EP1913130A2 (fr) | 2008-04-23 |
| CA2616712A1 (fr) | 2007-02-01 |
| JP2016127863A (ja) | 2016-07-14 |
| CA2616712C (fr) | 2015-11-17 |
| WO2007012764A3 (fr) | 2007-05-31 |
| US20090123431A1 (en) | 2009-05-14 |
| JP2015061536A (ja) | 2015-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8663652B2 (en) | Regeneration of endogenous myocardial tissue | |
| EP2902483B1 (en) | Method for in vitro proliferation of cell population containing cells suitable for treatment of ischemic disease | |
| Moccia et al. | Hematopoietic progenitor and stem cells circulate by surfing on intracellular Ca2+ waves: A novel target for cell-based therapy and anti-cancer treatment? | |
| CA2457694A1 (en) | Platelet-derived growth factor protection of cardiac myocardium | |
| JP6235639B2 (ja) | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 | |
| JPH03503167A (ja) | 部位指定血管形成素子とその使用法 | |
| EP0535148A1 (en) | Stimulation of bone marrow stromal and progenitor cells | |
| Chang et al. | High-mobility group box 1 accelerates distraction osteogenesis healing via the recruitment of endogenous stem/progenitor cells | |
| JP5390394B2 (ja) | 血管再生促進薬剤 | |
| CN101646463A (zh) | 具有治疗和诊断潜能的双特异性融合蛋白 | |
| Wu et al. | Characterization of two populations of human coronary artery endothelial cells1 | |
| JPWO2006112390A1 (ja) | 脂肪由来前駆細胞およびその利用 | |
| ES2366701T3 (es) | Técnicas in vitro para su uso con células madre. | |
| KR102400532B1 (ko) | 유도 혈관내피세포의 직접교차 분화 효율 및 혈관 형성능 증강을 위한 조성물 | |
| Shi | Interactions of early endothelial progenitor cells (EPC) and outgrowth endothelial cells (OEC) to improve the vascularization of bone tissue constructs | |
| JP2004269423A (ja) | Ｈｇｆ誘導体 |